Previous issue | Volume 97 | ESPE2023 | Next issue

61st Annual ESPE (ESPE 2023)

The Hague, Netherlands
21 Sep 2023 - 23 Sep 2023

Card image cap
The 61st ESPE Annual Meeting will now be taking place in The Hague, The Netherlands

Rapid Free Communications

Pituitary, neuroendocrinology and puberty 2

hrp0097rfc13.1 | Pituitary, neuroendocrinology and puberty 2 | ESPE2023

Are Glucagon-like peptide-1 (GLP-1) receptor agonists a new treatment option for hypothalamic obesity in the paediatric population: Preliminary experience from a tertiary paediatric endocrine centre

Chatterjee Sumana , Hawton Katherine , Giri Dinesh , Crowne Elizabeth

Background: Hypothalamic obesity (HO), defined as abnormal weight gain due to physical hypothalamic destruction, for example due to suprasellar tumours, is characterised by significant hyperphagia, lack of satiety, and rapid weight gain in the first year of hypothalamic insult. HO is not usually responsive to caloric restriction or lifestyle modification, and no pharmacotherapies are specifically approved for treating HO. GLP-1 agonists, which suppress appetit...

hrp0097rfc13.2 | Pituitary, neuroendocrinology and puberty 2 | ESPE2023

Arginine-stimulated copeptin is independent of GH secretion status

Binder Gerhard , Weber Karin , Peter Andreas , Schweizer Roland

Background: Copeptin is secreted in isomolar amounts along with arginine vasopressin peptide from the posterior pituitary. Its stability makes it a perfect candidate for the endocrine approach in the diagnosis of AVP deficiency. Arginine-stimulated copeptin is a possible alternative for the water deprivation test. We wondered whether basal and stimulated copeptin secretion is related to growth hormone secretion status or independent of it.<p class="abstext...

hrp0097rfc13.3 | Pituitary, neuroendocrinology and puberty 2 | ESPE2023

Treatment and outcome of the Dutch Childhood Craniopharyngioma Cohort study; first results after centralization of care

van Schaik Jiska , Schouten-van Meeteren Netteke , Vos-Kerkhof Evelien , Janssens Geert , Porro Giorgio , Fiocco Marta , Bakker Boudewijn , Tissing Wim , Hoving Eelco , van Santen Hanneke

Introduction: Childhood craniopharyngioma (cCP) has excellent survival, but quality of life may be severely hampered by hypothalamic dysfunction. We aimed to evaluate treatment and hypothalamic outcomes of a Dutch cCP cohort, and evaluate the effect of centralization of care.Methods: A retrospective cohort study was performed, including cCP patients diagnosed between 2004-2021. Treatment characteristics and hypothalamic ...

hrp0097rfc13.4 | Pituitary, neuroendocrinology and puberty 2 | ESPE2023

Trio analyses of patients with congenital hypopituitarism reveals novel candidate genes

de Azevedo Correa Fernanda , Habibi Imen , Kolesinska Zofia , Zouaghi Yassine , Zhai Jing , Phan-Hug Franziska , Antoniou Maria-Chiristina , Pignatelli Duarte , Lang-Muritano Mariarosaria , Marek Niedziela , l'Allemands Dagmar , Papadakis Georgios , Ameti Adelina , Messina Andrea , J. Niederlander Nicolas , Boizot Alexia , Santoni Federico , S. Acierno James , Pitteloud Nelly

Background: Congenital Hypopituitarism (CH) is a rare heterogeneous genetic disorder characterized by the deficiency of pituitary hormones. CH can be associated with extra pituitary phenotypes such as midline craniofacial malformations. To date, a minority of patients carry pathogenic variants in more than 30 genes, and thus more than 80% of cases remain unresolved.Objective: To identify de novo pathogenic variants in no...

hrp0097rfc13.5 | Pituitary, neuroendocrinology and puberty 2 | ESPE2023

Growth hormone and TSH deficiency after [177Lu]Lu-DOTATATE therapy for pediatric neuroblastoma; description of a first case.

van Wessel Karen , de Keizer Bart , Dierselhuis Miranda , van Santen Hanneke

Background: Neuroblastoma (NBL) is the most common extra cranial solid tumor in children. Endocrine adverse effects after treatment for NBL have been reported of which mainly caused by treatment with 131meta-iodobenzylguanidine ([131I]MIBG) or with alkylating agents and may consist of thyroid disorders, gonadal insufficiency or short stature. Due to recent developments patients are increasingly treated with [177Lu]Lu-DOTATATE peptide receptor radionuclide ther...

hrp0097rfc13.6 | Pituitary, neuroendocrinology and puberty 2 | ESPE2023

Pituitary size on volumetric MRI predicts the severity of the neuroendocrine phenotype in populations at risk

Cerbone Manuela , D'Arco Felice , A Spoudeas Helen , Clark Chris , T Dattani Mehul

Background: Hypopituitarism in children is a complex condition and its hierarchical evolution at different developmental windows is unpredictable. Magnetic resonance imaging (MRI) is helpful but largely a subjective assessment of anomalies of the hypothalamo-pituitary (H-P) structures. We aimed to test the utility of a quantitative measure of pituitary and stalk in predicting neuroendocrine phenotypes.Patients and Methods:</stron...